Skip to main content

Advertisement

Table 3 Characteristics of nine patients with HLA-A*0201

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Patient No EBV state Percentages of EBV-CTLs at + 30 days Percentages of EBV-CTLs at + 60 days Percentages of EBV-CTLs at + 90 days Time of CSA withdrawal aGVHD Result Cause of death
1 No 0.1982 2.9100 1.0950   no alive  
2 EBV-DNAemia 0.8337 1.9200 1.3644 20 Grade I alive  
3 No 0.7296 3.0000 1.0119 19 Grade I alive  
4 EBV-DNAemia 0.3252 3.1700 1.4483 Grade I alive  
5 EBV-DNAemia 0.0179 1.9000 1.1990 16 Grade I alive  
6 No 1.0790 4.2400 11 Grade I dead Aspergillus pneumonia
7 EBV-related disease 0.5619 0.6900 5 Grade I dead EBV encephalitis
8 EBV-related disease 0.2727 0.5300 no alive  
9 EBV-related disease 0.9600 0.5500 58 Grade I dead EBV enteritis
  1. Note: The patient who died at + 43 days was a 100% donor type by bone puncture and STR examination at + 30 days after transplantation. However, at + 33 days, this patient developed hyperthermia, pulmonary infection, and decreased blood cells and was found to have decreased chimerism to 23% of that of the donor recipient at + 37 days. Secondary graft failure was observed, which was thought to be related to the serious pulmonary fungal infection. We did not include this patient in this Table